Chikungunya vaccine clinical trials
Also written VLA1553.
How each study uses Chikungunya vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Chikungunya vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Nov 2023 · IXCHIQ · BLA 125777 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VLA1553
- 5
Studies by the year they started
7 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Valneva Austria GmbH (6) · Centre Hospitalier Universitaire de la Réunion (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Chikungunya vaccine.
- Jun 2027Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French GuianaPhase 4 · Centre Hospitalier Universitaire de la Réunion
Studies
Open first, then newest update. How each study uses Chikungunya vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French GuianaRecruitingPhase 4Centre Hospitalier Universitaire de la RéunionNCT06928753Written as IXCHIQ
- A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsCompletedPhase 2Valneva Austria GmbHNCT06106581Written as VLA1553 full dose
- Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)Active, not recruitingPhase 3Valneva Austria GmbHNCT04838444Written as VLA1553
- A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy ChildrenWithdrawnPhase 3Valneva Austria GmbHNCT07133178Written as VLA1553
- A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)WithdrawnPhase 3Valneva Austria GmbHNCT06028841Written as VLA1553
- Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in AdultsCompletedPhase 3Valneva Austria GmbHNCT04546724Written as VLA1553
- Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy VolunteersCompletedPhase 1Valneva Austria GmbHNCT03382964Written as VLA1553